BioTuesdays
TCR2 Therapeutics Logo
Markets

SVB Leerink ups TCR2 Therapeutics PT to $41 from $28

SVB Leerink raised its price target for TCR2 Therapeutics (NASDAQ:TCRR) to $41 from $28, citing positive interim data from the ongoing Phase 1 portion of the TC-210 Phase 1/2 clinical trial for mesothelin-expressing...

December 15, 2020
Aerpio Pharma Logo
Markets

BTIG starts Aerpio Pharma at buy: PT $4

BTIG launched coverage of Aerpio Pharmaceuticals (NASDAQ:ARPO) with a “buy” rating and $4 price target. The stock closed at $2 on Dec. 8. “Aerpio is marching forward with several clinical programs of its first-in-class...

December 9, 2020
Venus-Concept-Logo
Markets

Stifel starts Venus Concepts at hold; PT $2.50

Stifel initiated coverage of Venus Concepts (NASDAQ:VERO) with a “hold” rating and price target of $2.50, citing “more work to be done in improving ARTAS,” the company’s robotic hair restoration system. The stock closed...

December 9, 2020
Curis Logo
Markets

HCW ups Curis PT to $9 from $5

H.C. Wainwright raised its price target for Curis (NASDAQ:CRIS) to $9 from $5 after the company announced preliminary data from an ongoing Phase 1 study evaluating monotherapy, CA-4948, in relapsed or refractory acute...

December 8, 2020
Prothena
Markets

HCW starts Prothena at buy; PT $22

H.C. Wainwright launched coverage of Prothena (NASDAQ:PRTA) with a “buy” rating and price target of $22. The stock closed at $11.53 on Dec 4. Prothena is focused on protein-opathies affecting the central nervous system...

December 7, 2020
Markets

HCW starts BiomX at buy; PT $20

H.C. Wainwright initiated coverage of BiomX (NYSE American:PHGE) with a “buy” rating and $20 price target. The stock closed at $5.90 on Dec 4. “BiomX is one of the leaders in the development of bacteriophage (phage)...

December 7, 2020
Liquidia Logo
Markets

HCW starts Liquidia Technologies at buy; PT $6

H.C. Wainwright initiated coverage of Liquidia Technologies (NASDAQ:LQDA) with a “buy” rating and price target of $6. The stock closed at $2.92 on Dec. 3. Liquidia is focused on applying its particle engineering PRINT...

December 4, 2020
Syndax Pharma Logo
Markets

Stifel starts Syndax Pharmaceuticals at buy; PT $32

Stifel launched coverage of Syndax Pharmaceuticals (NASDAQ:SNDX) with a “buy” rating and price target of $32. The stock closed at $22.79 on Dec. 2. Analyst Konstantinos Aprilakis, M.D., writes that SNDX-5613, the...

December 3, 2020
Sutra-Biopharma-Logo
Markets

Stifel starts Sutro Biopharma at buy; PT $25

Stifel initiated coverage of Sutro Biopharma (NASDAQ:STRO) with a “buy” rating and $25 price target. The stock closed at $16.35 on Dec. 2. Sutro is developing XpressCF, a cell-free protein-synthesis platform that...

December 3, 2020
SQZ-Biotech-Logo
Markets

Analysts start SQZ Biotechnologies at buy

Analysts with Stifel and BTIG launched coverage of SQZ Biotechnologies (NYSE:SQZ) with “buy” ratings and price targets of $38 and $40, respectively. The stock closed at $27.62 on Nov. 23. “We believe SQZ’s Cell Squeeze...

November 24, 2020
Curis Logo
Markets

HCW starts Curis at buy; PT $5

H.C. Wainwright initiated coverage of Curis (NASDAQ:CRIS) with a “buy” rating and price target of $5. The stock closed at $1.35 on Nov. 23. Curis is developing two novel therapeutics for three potential indications that...

November 24, 2020
Biodesix Logo
Markets

Analysts start Biodesix at buy and OP

200 Analysts for Canaccord Genuity, BTIG and William Blair launched coverage of Biodesix (NASDAQ:BDSX) with “buy” and “outperform” ratings. Shares of Biodesix closed at $17.09 on Nov. 20. Canaccord analyst Max Masucci...

November 23, 2020
Silence-Therapeutics-Logo
Markets

BTIG starts Silence Therapeutics at buy; PT $32

BTIG initiated coverage of Silence Therapeutics (NASDAQ, AIM: SLN) with a “buy” rating and $32 price target. The stock closed at $16.70 on Nov. 17. The company is a development stage therapeutics company based on nearly...

November 18, 2020
IMAC-Logo
Markets

AGP starts IMAC Holdings at buy; PT $2.75

Alliance Global Partners launched coverage of IMAC Holdings (NASDAQ:IMAC) with a “buy” rating and price target of $2.75. The stock closed at $1.05 on Nov. 16. IMAC offers regenerative medicine treatments including...

November 17, 2020
Opthea-Logo
Markets

SVB Leerink starts Opthea at OP; PT $33

SVB Leerink launched coverage of Opthea (NASDAQ:OPT) with an “outperform” rating and $33 price target. The stock closed at $13.19 on Nov. 10. “The basis for our recommendation and valuation is our forecast for revenue...

November 11, 2020
Tarsus Pharmaceuticals Logo
Markets

Ladenburg starts Tarsus Pharma at buy; PT $42

Ladenburg Thalmann initiated coverage of Tarsus Pharmaceuticals (NASDAQ:TARS) with a “buy” rating and $42 price target. The stock closed at $23.19 on Nov. 19. Tarsus focuses on the development of novel treatments for...

November 10, 2020
PDS Biotechnology Logo
Markets

HCW ups PDS Biotechnology to buy; PT $6

H.C. Wainwright upgraded PDS Biotechnology (NASDAQ:PDSB) to “buy” from “neutral” with a price target of $6. The stock closed at $2.04 on Nov. 9. In March 2020, HCW downgraded PDS based on dilution, significantly reduced...

November 10, 2020
Syros-Logo
Markets

Brookline starts Syros Pharma at buy; PT $19

Brookline Capital Markets launched coverage of Syros Pharmaceuticals (NASDAQ:SYRS) with a “buy” rating and a 12-to-18-month price target of $19.00. The stock closed at $8.89 on Nov. 9. Syros is developing gene-control...

November 10, 2020

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.